Michael Siegel
Neurology · San Mateo, CANPI 1699794115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,999 and has fallen 98.9% since, to $22 in 2025.
Across 274 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adamas Pharmaceuticals, Inc.$589
- SK Life Science, Inc.$503
- Acadia Pharmaceuticals Inc$474
- AbbVie$417
- Eisai Inc.$358
- Teva Pharmaceuticals USA, Inc.$330
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$1233%
- Food & beverage$4,57797%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adamas Pharmaceuticals, Inc. | 48 | $589 |
| SK Life Science, Inc. | 19 | $503 |
| Acadia Pharmaceuticals Inc | 31 | $474 |
| AbbVie(2 entities) | 40 | $417 |
| Eisai Inc. | 30 | $358 |
| Teva Pharmaceuticals USA, Inc. | 22 | $330 |
| Amgen | 11 | $273 |
| Maculogix, Inc. | 1 | $257 |
| Neurocrine Biosciences, Inc. | 17 | $237 |
| AstraZeneca | 2 | $218 |
| Lilly USA, LLC | 8 | $157 |
| Avanir Pharmaceuticals, Inc. | 8 | $155 |
| Biohaven Pharmaceuticals, Inc. | 7 | $153 |
| UCB, Inc. | 7 | $144 |
| Acorda Therapeutics, Inc | 6 | $123 |
| Kyowa Kirin, Inc. | 5 | $89 |
| MDD US Operations, LLC | 4 | $74 |
| Vertical Pharmaceuticals, LLC | 2 | $37 |
| Bausch Health US, LLC | 2 | $36 |
| Almatica Pharma LLC | 1 | $24 |
| Abbott | 1 | $22 |
| Biogen | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,710 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 24 | $2,554 |
| Levetiracetam | 34 | $1,838 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 40 | $1,624 |
| Lamotrigine | 13 | $1,047 |
| Duloxetine Hcl | 16 | $656 |
| Divalproex Sodium | 20 | $563 |
| Donepezil Hcl | 22 | $541 |
| Phenytoin Sodium Extended | 13 | $313 |
| Gabapentin | 15 | $74 |
| Topiramate | 20 | $55 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Mateo
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.